Literature DB >> 20033200

Neurocognitive dysfunction in adult moyamoya disease.

Joanne R Festa1, Lauren R Schwarz, Neil Pliskin, C Munro Cullum, Laura Lacritz, Fady T Charbel, Dana Mathews, Robert M Starke, E Sander Connolly, Randolph S Marshall, Ronald M Lazar.   

Abstract

We wanted to determine the neurocognitive profile of adult patients with moyamoya disease prior to neurosurgical intervention. The experience of three United States medical centers, Columbia University, University of Illinois at Chicago, and the University of Texas Southwestern Medical Center at Dallas, were combined. Clinical data from adult patients (N = 29) referred for neuropsychological evaluation from 1996 to 2008 were reviewed. Neurocognitive functioning was assessed using standardized neuropsychological tests and all data were converted to z-scores. Memory, attention, processing speed, verbal memory, visuo-spatial, language, and executive functions were examined. Cognitive dysfunction was defined as performance in two or more cognitive domains 1.5 standard deviations below age-corrected normative means OR one or more cognitive domains two standard deviations below age-corrected normative means. Manual strength and dexterity, as well as depressive symptoms, were also assessed. Two-thirds of patients demonstrated neurocognitive dysfunction. A large proportion of patients were found to have pronounced cognitive dysfunction (>2 SD below the mean) on tests of processing speed (29%), verbal memory (31%), verbal fluency (26%) and executive function (25%). Manual strength and dexterity were also affected in many patients, with impairment found in 36-58% of patients. Twenty-eight percent of patients reported moderate to severe depression, but depressive symptoms did not correlate with neurocognitive findings. A large proportion of adults with moyamoya disease demonstrate disruption of neurocognition in a broad range of functions, particularly those mediated by subcortical and frontal regions. The pattern of deficits suggests a mechanism of diffuse small vessel disease possibly caused by chronic hypoperfusion.

Entities:  

Mesh:

Year:  2009        PMID: 20033200     DOI: 10.1007/s00415-009-5424-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Neuropsychological and perfusion MR imaging correlates of revascularization in a case of moyamoya syndrome.

Authors:  A L Jefferson; G Glosser; J A Detre; G Sinson; D S Liebeskind
Journal:  AJNR Am J Neuroradiol       Date:  2006-01       Impact factor: 3.825

2.  Clinical features, surgical treatment, and long-term outcome in adult patients with moyamoya disease. Clinical article.

Authors:  Robert M Starke; Ricardo J Komotar; Zachary L Hickman; Yehuda E Paz; Angela G Pugliese; Marc L Otten; Matthew C Garrett; Mitchell S V Elkind; Randolph S Marshall; Joanne R Festa; Philip M Meyers; E Sander Connolly
Journal:  J Neurosurg       Date:  2009-11       Impact factor: 5.115

3.  Moyamoya disease in Europe, past and present status.

Authors:  Y Yonekawa; N Ogata; Y Kaku; E Taub; H G Imhof
Journal:  Clin Neurol Neurosurg       Date:  1997-10       Impact factor: 1.876

4.  Clinical features and outcome in North American adults with moyamoya phenomenon.

Authors:  Christopher L Hallemeier; Keith M Rich; Robert L Grubb; Michael R Chicoine; Christopher J Moran; DeWitte T Cross; Gregory J Zipfel; Ralph G Dacey; Colin P Derdeyn
Journal:  Stroke       Date:  2006-04-27       Impact factor: 7.914

5.  Neural damage caused by cerebral hyperperfusion after arterial bypass surgery in a patient with moyamoya disease: case report.

Authors:  Kuniaki Ogasawara; Nobukazu Komoribayashi; Masakazu Kobayashi; Takeshi Fukuda; Takashi Inoue; Keiko Yamadate; Akira Ogawa
Journal:  Neurosurgery       Date:  2005-06       Impact factor: 4.654

6.  Moyamoya disease in Europeans.

Authors:  Markus Kraemer; Wilhelm Heienbrok; Peter Berlit
Journal:  Stroke       Date:  2008-09-11       Impact factor: 7.914

7.  Neuropsychological performance in Moya Moya disease: a case study.

Authors:  R A Bornstein
Journal:  Int J Neurosci       Date:  1985-04       Impact factor: 2.292

8.  White matter hyperintensities and subclinical infarction: associations with psychomotor speed and cognitive flexibility.

Authors:  Clinton B Wright; Joanne R Festa; Myunghee C Paik; Alexis Schmiedigen; Truman R Brown; Mitsuhiro Yoshita; Charles DeCarli; Ralph Sacco; Yaakov Stern
Journal:  Stroke       Date:  2008-02-07       Impact factor: 7.914

9.  National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards.

Authors:  Vladimir Hachinski; Costantino Iadecola; Ron C Petersen; Monique M Breteler; David L Nyenhuis; Sandra E Black; William J Powers; Charles DeCarli; Jose G Merino; Raj N Kalaria; Harry V Vinters; David M Holtzman; Gary A Rosenberg; Anders Wallin; Martin Dichgans; John R Marler; Gabrielle G Leblanc
Journal:  Stroke       Date:  2006-08-17       Impact factor: 7.914

10.  Cognitive, emotional, and quality of life outcomes in patients with pulmonary arterial hypertension.

Authors:  Joanne White; Ramona O Hopkins; Eric W Glissmeyer; Natalie Kitterman; C Gregory Elliott
Journal:  Respir Res       Date:  2006-03-31
View more
  17 in total

1.  "STA-MCA bypass with encephalo-duro-myo-synangiosis combined with bifrontal encephalo-duro-periosteal-synangiosis" as a one-staged revascularization strategy for pediatric moyamoya vasculopathy.

Authors:  Giuseppe Esposito; Annick Kronenburg; Jorn Fierstra; Kees P J Braun; Catharina J M Klijn; Albert van der Zwan; Luca Regli
Journal:  Childs Nerv Syst       Date:  2015-02-27       Impact factor: 1.475

2.  Influence of Moyamoya disease on psychopathological abnormality in young males in Korea: analysis of multiphasic personal inventory test.

Authors:  Chang Hyun Oh; Hyeonseon Park; Eunyoung Kim; Dong-Keun Hyun; Joonho Chung
Journal:  Neurol Sci       Date:  2012-08-01       Impact factor: 3.307

3.  Functional cortical and cerebellar reorganization in a case of moyamoya disease.

Authors:  Rocco S Calabrò; Placido Bramanti; Annalisa Baglieri; Francesco Corallo; Rosaria De Luca; Simona De Salvo; Silvia Marino
Journal:  Innov Clin Neurosci       Date:  2015 Jan-Feb

4.  Selective neuropsychological impairments and related clinical factors in children with moyamoya disease of the transient ischemic attack type.

Authors:  Yen-Hsuan Hsu; Meng-Fai Kuo; Mau-Sun Hua; Chi-Cheng Yang
Journal:  Childs Nerv Syst       Date:  2013-09-05       Impact factor: 1.475

5.  Moyamoya syndrome causing stroke in young women with type 1 diabetes.

Authors:  Jing W Hughes; Jennifer A Wyckoff; Abby S Hollander; Colin P Derdeyn; Janet B McGill
Journal:  J Diabetes Complications       Date:  2016-08-12       Impact factor: 2.852

6.  Neuropsychological impairment in adults with moyamoya angiopathy: preoperative assessment and correlation to MRI and H215O PET.

Authors:  Constantin Roder; Patrick Haas; Monika Fudali; Monika Milian; Ulrike Ernemann; Philipp T Meyer; Marcos Tatagiba; Nadia Khan
Journal:  Neurosurg Rev       Date:  2019-11-14       Impact factor: 3.042

7.  Reorganization of the Brain Structural Covariance Network in Ischemic Moyamoya Disease Revealed by Graph Theoretical Analysis.

Authors:  Peijing Wang; Wenjie Li; Huan Zhu; Xingju Liu; Tao Yu; Dong Zhang; Yan Zhang
Journal:  Front Aging Neurosci       Date:  2022-06-02       Impact factor: 5.702

Review 8.  Cognitive Dysfunction Survey of the Japanese Patients with Moyamoya Disease (COSMO-JAPAN Study): study protocol.

Authors:  Yasushi Takagi; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-02-20       Impact factor: 1.742

9.  Mapping altered brain connectivity and its clinical associations in adult moyamoya disease: A resting-state functional MRI study.

Authors:  Ken Kazumata; Khin Khin Tha; Haruto Uchino; Masaki Ito; Naoki Nakayama; Takeo Abumiya
Journal:  PLoS One       Date:  2017-08-04       Impact factor: 3.240

10.  Neurocognitive Dysfunction According to Hypoperfusion Territory in Patients With Moyamoya Disease.

Authors:  Chang Gu Kang; Min Ho Chun; Jung-A Kang; Kyung Hee Do; Su Jin Choi
Journal:  Ann Rehabil Med       Date:  2017-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.